Circulating endothelial cells and their subpopulations: Role as predictive biomarkers in antiangiogenic therapy for colorectal cancer

Mariangela Manzoni, Giuditta Comolli, Martina Torchio, Giuliano Mazzini, Marco Danova

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical activities inadequate if based only on the reduction of the tumor dimensions, as this may not reflect their true biologic efficacy. Thus, it is crucial to identify biomarkers that permit the recognition of potentially responsive subjects and to spare toxicity in those who are unlikely to benefit from treatment. Circulating endothelial cells (CECs) have been recently indicated as potential surrogate biomarkers of angiogenesis in several types of cancer. The possibility of rapidly quantifying these cells represents a promising tool for monitoring the clinical outcome of tumors with the potential to assess response to various treatments. However, the identification and quantification of CECs is technically difficult and not well standardized. A variety of methods to detect CECs in patients with solid tumors have been used; these are based on different technical approaches, combinations of surface markers, sample handling, and staining protocols. With an expanding interest in the field of potential clinical applications for CECs in oncology, the development of standardized protocols for analysis is mandatory. The aim of this review was to critically summarize the available data concerning the clinical value of CECs and their subpopulations as biomarkers of antiangiogenic therapy in patients with metastatic colorectal cancer.

Original languageEnglish
Pages (from-to)11-17
Number of pages7
JournalClinical Colorectal Cancer
Volume14
Issue number1
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Colorectal Neoplasms
Endothelial Cells
Biomarkers
Neoplasms
Therapeutics
Cytostatic Agents
Staining and Labeling
Neoplasm Metastasis
Growth

Keywords

  • Angiogenesis
  • Biomarkers
  • Circulating endothelial cell
  • Colorectal cancer
  • Flow cytometry

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Medicine(all)

Cite this

Circulating endothelial cells and their subpopulations : Role as predictive biomarkers in antiangiogenic therapy for colorectal cancer. / Manzoni, Mariangela; Comolli, Giuditta; Torchio, Martina; Mazzini, Giuliano; Danova, Marco.

In: Clinical Colorectal Cancer, Vol. 14, No. 1, 01.03.2015, p. 11-17.

Research output: Contribution to journalArticle

@article{774a6456d4694e1eae2bed78d137efba,
title = "Circulating endothelial cells and their subpopulations: Role as predictive biomarkers in antiangiogenic therapy for colorectal cancer",
abstract = "Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical activities inadequate if based only on the reduction of the tumor dimensions, as this may not reflect their true biologic efficacy. Thus, it is crucial to identify biomarkers that permit the recognition of potentially responsive subjects and to spare toxicity in those who are unlikely to benefit from treatment. Circulating endothelial cells (CECs) have been recently indicated as potential surrogate biomarkers of angiogenesis in several types of cancer. The possibility of rapidly quantifying these cells represents a promising tool for monitoring the clinical outcome of tumors with the potential to assess response to various treatments. However, the identification and quantification of CECs is technically difficult and not well standardized. A variety of methods to detect CECs in patients with solid tumors have been used; these are based on different technical approaches, combinations of surface markers, sample handling, and staining protocols. With an expanding interest in the field of potential clinical applications for CECs in oncology, the development of standardized protocols for analysis is mandatory. The aim of this review was to critically summarize the available data concerning the clinical value of CECs and their subpopulations as biomarkers of antiangiogenic therapy in patients with metastatic colorectal cancer.",
keywords = "Angiogenesis, Biomarkers, Circulating endothelial cell, Colorectal cancer, Flow cytometry",
author = "Mariangela Manzoni and Giuditta Comolli and Martina Torchio and Giuliano Mazzini and Marco Danova",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.clcc.2014.12.002",
language = "English",
volume = "14",
pages = "11--17",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Circulating endothelial cells and their subpopulations

T2 - Role as predictive biomarkers in antiangiogenic therapy for colorectal cancer

AU - Manzoni, Mariangela

AU - Comolli, Giuditta

AU - Torchio, Martina

AU - Mazzini, Giuliano

AU - Danova, Marco

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical activities inadequate if based only on the reduction of the tumor dimensions, as this may not reflect their true biologic efficacy. Thus, it is crucial to identify biomarkers that permit the recognition of potentially responsive subjects and to spare toxicity in those who are unlikely to benefit from treatment. Circulating endothelial cells (CECs) have been recently indicated as potential surrogate biomarkers of angiogenesis in several types of cancer. The possibility of rapidly quantifying these cells represents a promising tool for monitoring the clinical outcome of tumors with the potential to assess response to various treatments. However, the identification and quantification of CECs is technically difficult and not well standardized. A variety of methods to detect CECs in patients with solid tumors have been used; these are based on different technical approaches, combinations of surface markers, sample handling, and staining protocols. With an expanding interest in the field of potential clinical applications for CECs in oncology, the development of standardized protocols for analysis is mandatory. The aim of this review was to critically summarize the available data concerning the clinical value of CECs and their subpopulations as biomarkers of antiangiogenic therapy in patients with metastatic colorectal cancer.

AB - Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical activities inadequate if based only on the reduction of the tumor dimensions, as this may not reflect their true biologic efficacy. Thus, it is crucial to identify biomarkers that permit the recognition of potentially responsive subjects and to spare toxicity in those who are unlikely to benefit from treatment. Circulating endothelial cells (CECs) have been recently indicated as potential surrogate biomarkers of angiogenesis in several types of cancer. The possibility of rapidly quantifying these cells represents a promising tool for monitoring the clinical outcome of tumors with the potential to assess response to various treatments. However, the identification and quantification of CECs is technically difficult and not well standardized. A variety of methods to detect CECs in patients with solid tumors have been used; these are based on different technical approaches, combinations of surface markers, sample handling, and staining protocols. With an expanding interest in the field of potential clinical applications for CECs in oncology, the development of standardized protocols for analysis is mandatory. The aim of this review was to critically summarize the available data concerning the clinical value of CECs and their subpopulations as biomarkers of antiangiogenic therapy in patients with metastatic colorectal cancer.

KW - Angiogenesis

KW - Biomarkers

KW - Circulating endothelial cell

KW - Colorectal cancer

KW - Flow cytometry

UR - http://www.scopus.com/inward/record.url?scp=84922750384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922750384&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2014.12.002

DO - 10.1016/j.clcc.2014.12.002

M3 - Article

C2 - 25591800

AN - SCOPUS:84922750384

VL - 14

SP - 11

EP - 17

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 1

ER -